Orientbio오리엔트바이오
002630 · KOSPI · ₩002630 · 오리엔트바이오
₩1,190▼ ₩39 (3.17%)End-of-day · Oct 30, 2026 · End-of-day prices.
Margins
| TTM | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Gross margin | 30.0% | 24.5% | 34.2% | 34.1% | 34.3% | 24.6% |
| Operating margin | −5.0% | −10.5% | −2.3% | 5.0% | −14.4% | −20.6% |
| Net margin | −22.3% | −44.9% | 46.0% | −43.1% | 130.1% | −80.6% |
Growth (year on year)
| TTM | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Revenue growth | −3.7% | +5.0% | −2.8% | +9.7% | +4.3% | — |
| Operating income growth | +54.4% | −376.3% | −144.5% | +138.4% | +27.2% | — |
| Net income growth | +52.1% | −202.5% | +203.6% | −136.3% | +268.3% | — |
Returns
| TTM | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Return on equity | −8.8% | −16.8% | 16.4% | −16.1% | 55.0% | −49.3% |
| Return on assets | −7.5% | −14.5% | 14.5% | −13.4% | 40.9% | −32.6% |
Leverage and liquidity
| TTM | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Liabilities to equity | 15.4% | 18.0% | 14.0% | 13.5% | 26.2% | 51.3% |
| Net debt to equity | −52.5% | −45.1% | −48.3% | −6.4% | −28.8% | 4.6% |
| Current ratio | 1,409.3% | 1,126.1% | 1,402.1% | 1,265.3% | 516.7% | 165.3% |
Calculated from filed financial statements. TTM = trailing 12 months.
Also known as: Orientbio / 오리엔트바이오 / 002630 / KRX:002630
Source: KRX statistical information